
Moderna (MRNA) Stock 3.6% Down in Premarket, CEO Says Coronavirus Vaccine to Be Affordable
Moderna (MRNA) stock has fallen since the last week’s announcement of a possible vaccine for COVID-19. Its CEO has indicated that the prices for the coronavirus vaccine will be affordable.